Making cost assessments based on RCTs more useful to decision-makers

Health Policy

Volumn 37, Issue 3, 1996, Pages 163-183

  Baltussen, Rob ^a   Ament, André ^a   Leidl, Reiner ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Bias; Clinical trial; Cost estimation; Decision making; Economic evaluation

Indexed keywords

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; HEALTH CARE COST; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0030016809     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8510(96)90023-8     Document Type: Article

References (44)

1. US Congress, Office of Technology Assessment, Identifying Health Technologies that Work: Searching for Evidence, OTA-H-60, US Government Printing Office, Washington DC, 1994.
2. Spilker, B., Guide to Clinical Trials, Raven Press, New York, 1991.
3. Drummond, M.F. and Davies, L., Economic analysis alongside clinical trials: revisiting the methodological issues, International Journal of Technology Assessment in Health Care, 7 (1991) 561-573.
4. Petrou, S., Malek, M. and Davey, P.G., The reliability of cost-utility estimates in cost-per-QALY league tables, Pharmacoeconomics, 3 (1993) 345-353.
5. Luce, B.R., Cost-effectiveness analysis: obstacles to standardisation and its use in regulating pharmaceuticals, Pharmacoeconomics, 3 (1993) 1-9.
6. Luce, B.R. and Elixhauser, A., Estimating costs in the economic evaluation of medical technologies, International Journal of Technology Assessment in Health Care, 6 (1990) 57-76.
7. Garber, A.M., Competing risks and the cost-effectiveness of health interventions (1989 Annual Meeting Program and Abstracts), Medical Decision Making, 9 (1989) 319.
8. Hoogenveen, R.T., Verkley, H. and Jager, J.C., Verkennende Studie betreffende concurrerende en vervangende doodsoorzaken in verband met kwantitatieve gezondheidsdoelen (Explanatory study concerning concurrent and replacing causes of death in relation to quantitative health goals), Report nr. 958606 004, RIVM, Bilthoven, 1990 (in Dutch).
9. Rijksinstituut voor Volksgezondheid en Milieuhygiene (RIVM), Volksgezondheid Toekomst Verkenning: De gezondheidstoestand van de Nederlandse bevolking in de periode 1950-2010 (The health status of the Dutch population in the period 1950-2010), Chapter 4, Sdu Uitgeverij Plantijnstraat, The Hague, 1993 (in Dutch).
10. Duin, van C.M. and Hofman, A., Relation between nicotine intake and cancer conference, British Medical Journal, 302 (1991) 1491-1494.
11. Blaker, D., Detsky, A., Firestone, T., Hubbard, E., Kennedy, W., Koncahk, R., Menon, D., Schubert, F., Olver, R. and Tugwell, P., Guidelines for Economic Evaluation of Pharmaceuticals, Canada, Ottawa, 1994.
12. Commonwealth Department of Health, Guidelines for the Pharmaceutical Industry on Preparation of Submission to the Pharmaceutical Benefits Advisory Committee, Australian Government Publishing Service, Canberra, 1992.
13. Drummond, M.F., Stoddart, G.L. and Torrancc, G.W., Methods for the Economic Evaluation of Health Care Programmes, Oxford University Press, London, 1987.
14. Schechter, C.B., Rose, D.N., Fahs, M.C. and Silver, A.L., Tuberculin screening: cost-effectiveness analysis of various testing schedules, American Journal of Preventive Medicines, 6 (1990) 167-175.
15. Paltiel, A.D. and Kaplan, E.H., Modelling Zidovudine therapy: a cost-effectiveness analysis. Journal of the Acquired Immune Deficiency Syndrome, 4 (1991) 795-804.
16. Rutten, F.H., Bonsel, G.J. and Uyl-de Groot, C.A., Economic evaluation and clinical trials - methodological and clinical aspects. In M. Chytil, G. Duru and W. van Eimeren (Eds), The Challenge of Change. Fifth International Conference on System Science in Health Care. Omnipress, Prague, 1992.
17. Fletcher, R.H., Fletcher, S.W. and Wagner, E.H., Clinical Epidemiology: The Essentials, Williams and Wilkins, Baltimore, 1988.
18. Urquhart, J. and Chevalley, C., Impact of unrecognized dosing errors on the cost and effectiveness of pharmaceuticals, Drug Information Journal, 22 (1988) 363-378.
19. Averill, R.F., McGuire, T.E., Manning, B.E., Fowler, D.A., Horn, S.D., Dickson, P.S., Coye, M.J., Knowlton, D.L. and Bender, J.A., A study of the relationship between severity of illness and hospital costs in New Jersey hospitals, Health Services Research, 27 (1992) 587-605.
20. Woods, J.R., Saywell, R.M., Nijhuis, A.W., Jay, S.J., Lohrman, R.G. and Halbrook, H.G., The learning curve and the costs of heart transplantation, Health Services Research, 27 (1992) 219-238.
21. Voss, G.B.W.E., Severity of Illness and Costs of Medical Care in Patients with Acute Myocardial Infarction, Thesis, Universitaire Pers Maastricht, Maastricht, 1993.
22. Gerard, K. and Mooney, G., QALY league tables: Handle with care. Health Economics, 2 (1993) 59-64.
23. Mitchell, J.B., Time trends in inpatient physician spending. Health Services Research, 28 (1993) 641-660.
24. Horneffer, P.J., Gardner, T.J. and Monolio, T.A., The effects of age on outcome after coronary bypass surgery, Circulation, 76 (1987) 6.
25. Guyatt, G., Drummond, M., Feeney, D., Tugwell, P., Stoddart, G., Haynes, R.B., Bennett, K. and Labelle, R., Guidelines for the clinical and economic evaluation of health care technologies, Social Science and Medicine, 22 (1986) 393-408.
26. Baltussen, R., Leidl, R. and Ament, A., The impact of age on the cost-effectiveness of medical interventions and its control in decision-making, Health Economics, 5 (1996) in press.
27. Custer, W.S. and Willke, R.J., Teaching hospital costs: the effects of medical staff characteristics, Health Services Research, 25 (1991) 831-857.
28. Grannemann, T.W., Brown, R.S. and Pauly, M.V., Estimating hospital costs: a multiple-output analysis, Journal of Health Economics, 5 (1986) 107-127.
29. Lieberman, M.B., The learning curve and pricing in the chemical pricing industries, RAND Journal of Economics, 15 (1984) 213-228.
30. Belkaoui, A., The Learning Curve, Quorum Books, Westport, CT, 1986
31. Hannan, E.L., Kilburn, H., O'Donell, J.F., Bernard, H.R., Shieds, E.P., Lindsey, M.L. and Yazici. A., A longitudinal analysis of the relationship between in-hospital mortality in New York State and the volume of abdominal aortic aneurysm surgeries performed, Health Services Research, 27 (1992) 517-542.
32. Burns, L.R. and Wholey, D.R., The effects of patient, hospital, and physician characteristics on length of stay and mortality, Medical Care, 29 (1991) 251-271.
33. Leidl, R., Some factors to consider when using the results of economic evaluation studies at the population level, International Journal of Technology Assessment, 10 (1994) 467-478.
34. Kesteloot, K. and Penninckx, F., The costs and effects of open versus laparoscopic cholecystectomies, Health Economics, 2 (1993) 303-312.
35. Drummond, M.F., Bloom, B.S., Carrin, G., Hillman, A.L., Hutchings, H.C., Knill-Jones, R.P., Pouvourville de, P. and Torfs, K., Issues in the cross-national assessment of health technology. International Journal of Technology Assessment in Health Care, 8 (1992) 671-682.
36. Hannan, E.L., O'Donnell, J.F., Kilburn, H., Bernhard, H.R. and Yazici, A., Investigation of the relationship between volume and mortality for surgical procedures performed in New York States hospitals, Journal of the American Medical Association, 262 (1989) 503-510.
37. Kelly, J.V. and Hellinger, F.J., Heart disease and hospital deaths: an empirical study, Health Service Research, 22 (1987) 369-395.
38. Leidl, R., A survey of the economic evaluation of early drug intervention in HIV infection. In E. Kaplan and M. Brandeau (Eds), Modelling the AIDS Epidemic: Planning, Policy, and Prediction, Raven Press, New York, 1983, pp. 253-271.
39. Leidl, R., Standardisierung und Flexibilisierung ökonomischer Evaluationsstudien (Standardising and flexibilisation of economic evaluation studies). In J.H. Trampisch and S. Lange (Eds), Medizinische Forschung - Ärztliches Handeln; 40. Jahrestagung der GMDS, Bochum, September 1995, MMV Medizin, München, 1995, pp. 285-289 (in German).
40. Sclar, D.A., Tartaglione, T.A. and Fine, M.J., Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases, Infectious Agents and Disease, 3 (1994) 266-273.
41. Tugwell, P., Bennett, K.J., Sackett, D.L. and Haynes, R.B., The measurement iterative loop: a framework for the critical appraisal of need, benefits and costs of health interventions, Journal of Chronic Diseases, 38 (1985) 339-351.
42. Goldberg, H.J., Cummings, M.A., Steinberg, E.P., Ricci, E.M., Shannon, T., Soumerai, S.B., Mittman, B.S., Eisenberg, J., Heck, D.A., Kaplan, S. et al., Deliberations on the dissemination of PORT products: translating research findings into improved patient outcomes, Medical Care 32 (1994), Supplement, JS90-110.
43. Drugs Programs Branch, Ontario Guidelines for Economic Analysis of Pharmaceutical Products, Ministry of Health, Ontario, 1993.
44. Banta, H.D. and Luce, B.R., Health Care Technology and its Assessment, Oxford University Press. New York, 1993.